Abstract
The outcome of patients with aggressive refractory diffuse large B-cell lymphoma (DLCL) is generally poor. A 43-year-old female with DLCL, who relapsed after first line chemotherapy (CHOP-cyclophosphamide, doxorubicin, vincristine, and prednisone) and progressed despite salvage chemotherapy (EPOCH-etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin), was treated effectively with 8 cycles of Rituximab. She is without evidence of disease with a follow-up of 32 months. We report this case to bring to attention the possibility of sustained durable remission with single agent Rituximab in refractory DLCL.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2235-2236 |
| Number of pages | 2 |
| Journal | Leukemia and Lymphoma |
| Volume | 43 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 1 2002 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Diffuse large B-cell lymphoma
- Lymphoma
- Rituxan
- Rituximab
Fingerprint
Dive into the research topics of 'Rituximab provides durable remission in a patient with refractory aggressive diffuse B-cell lymphoma failing salvage chemotherapy'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS